

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

10 Jun 2026

### **A comparative study of labetalol and esmolol intravenous infusion in the prevention of cardiovascular complications and ischemic changes in patients with chronic hypertension during cataract surgery under local anesthesia with sedation**

#### **Protocol summary**

##### **Study aim**

If it is determined that each of the drugs esmolol and labetalol by intravenous injection method are more effective in preventing cardiovascular complications in patients with chronic hypertension during cataract surgery by local anesthesia and sedation, they can be used routinely.

##### **Design**

Clinical trial without control group, with parallel group, triple blind, randomized, phase 3 on 70 patients, random allocation software was used for randomization.

##### **Settings and conduct**

A triple blind clinical trial in patients with chronic hypertension who are candidates for cataract surgery. The Patients will be under local anesthesia with sedation, and then 5 minutes before the surgery, the first group will be treated with esmolol and the second group will be treated with labetalol, and during the operation, the vital signs of both groups will be recorded and examined. The above study is conducted in Faiz Medical Center

##### **Participants/Inclusion and exclusion criteria**

Patients who will be included in the study: 1- Candidate patients for cataract surgery with local anesthesia and sedation based on ASA III-II criteria 2-Patients over 65 years of age and of both sexes with chronic hypertension treated with calcium channel blockers and angiotensin converting enzyme inhibitors Patients who are not eligible for the study: 1-Patients who have a history of drug allergy 2-Patients who have addictions.

##### **Intervention groups**

In the first group, 0.5 mg/kg intravenous esmolol, whose volume will be increased to 20 cc by sterile normal saline, will be intravenously infused within two minutes, then in the second group, 0.2 mg/kg intravenous labetalol, whose volume will be increased to 20 cc by sterile normal saline. 20 cc will be delivered and will be

intravenously infused within two minutes.

##### **Main outcome variables**

Systolic blood pressure, diastolic blood pressure, heart rate, breathing rate, arterial oxygen saturation

#### **General information**

##### **Reason for update**

##### **Acronym**

##### **IRCT registration information**

IRCT registration number: **IRCT20221108056442N1**

Registration date: **2022-11-26, 1401/09/05**

Registration timing: **prospective**

Last update: **2022-11-26, 1401/09/05**

Update count: **0**

##### **Registration date**

2022-11-26, 1401/09/05

##### **Registrant information**

##### **Name**

Amirreza Abbasi

##### **Name of organization / entity**

##### **Country**

Iran (Islamic Republic of)

##### **Phone**

+98 74 3262 0262

##### **Email address**

amirrezaabbasi00@gmail.com

##### **Recruitment status**

**Recruitment complete**

##### **Funding source**

##### **Expected recruitment start date**

2022-12-22, 1401/10/01

##### **Expected recruitment end date**

2023-03-20, 1401/12/29

**Actual recruitment start date**

empty

**Actual recruitment end date**

empty

**Trial completion date**

empty

**Scientific title**

A comparative study of labetalol and esmolol intravenous infusion in the prevention of cardiovascular complications and ischemic changes in patients with chronic hypertension during cataract surgery under local anesthesia with sedation

**Public title**

Esmolol and Labetalol in cataract surgery in patient with chronic hypertension.

**Purpose**

Prevention

**Inclusion/Exclusion criteria**

**Inclusion criteria:**

Candidate patients for cataract surgery Patients over 65 years old

**Exclusion criteria:**

History of drug allergy Addiction

**Age**

From **65 years** old

**Gender**

Both

**Phase**

3

**Groups that have been masked**

- Participant
- Investigator
- Data analyser

**Sample size**

Target sample size: **70**

**Randomization (investigator's opinion)**

Randomized

**Randomization description**

In this study, the simple randomization method of block randomization (block randomization) we will use. Blocking is usually in order Balance the number of samples assigned to each group To be used in the study. This feature helps researchers to Items that require intermediate analyzes during the sampling process The number of samples assigned to each of the case groups Study is equal. The size of all the blocks is equal and we are in this We will have a three-group trial of 6 blocks of 15. Randomization tools are also used in sequence generation software Random (software allocation Random) is used that Random sequence generation software in addition to simple randomization capable To generate random sequences by block generation method. For hiding We avoid concealment allocation We use the method used to execute the sequence Random refers to study participants, in a way That before the individual is assigned, the assigned group is not specified. With From opaque envelopes sealed in random sequence (envelopes opaque, sealed, numbered

Sequentially) in This method uses each of the random sequences created on a card It is registered and the cards are placed in the letter envelopes in order To be. In order to maintain a random sequence, also on the outer surface of the envelope The numbering is done in the same way. Finally the envelope lid The letters are pasted and placed in a box, respectively. At Time to start registration of participants, based on the order of entry of the company Eligible applicants to open one of the envelopes in order And the assigned group of the participant will be revealed.

**Blinding (investigator's opinion)**

Triple blinded

**Blinding description**

The researcher, patients and project partner who will perform the statistical analysis will not be aware of the study (triole blind). The grouping of patients will be recorded on a sheet and given to one of the project colleagues. Patients will receive the standard treatment, but they will not know the type of medicine received.

**Placebo**

Not used

**Assignment**

Parallel

**Other design features**

**Secondary Ids**

empty

**Ethics committees**

**1**

**Ethics committee**

**Name of ethics committee**

Ethics committee of Isfahan University of Medical Sciences

**Street address**

Block 8 , Hezarjerib Ave , Bahar St

**City**

Esfahan

**Province**

Isfahan

**Postal code**

8169615738

**Approval date**

2022-11-08, 1401/08/17

**Ethics committee reference number**

IR.MUI.MED.REC.1401.285

**Health conditions studied**

**1**

**Description of health condition studied**

Cardiovascular complications and ischemic changes in patients with chronic hypertension during cataract surgery

**ICD-10 code**

**ICD-10 code description**

## Primary outcomes

### 1

#### Description

Heart Rate

#### Timepoint

Before the start of the operation, 5 minutes after the start of the operation, every 15 minutes until the end of the operation

#### Method of measurement

Cardiac Monitor device

### 2

#### Description

Systolic Blood Pressure

#### Timepoint

Before the start of the operation, 5 minutes after the start of the operation, every 15 minutes until the end of the operation

#### Method of measurement

In millimeters of mercury using a Calibrated Barometer

### 3

#### Description

Diastolic Blood pressure

#### Timepoint

Before the start of the operation, 5 minutes after the start of the operation, every 15 minutes until the end of the operation

#### Method of measurement

In millimeters of mercury using a Calibrated Barometer

### 4

#### Description

Percentage of oxygen Saturation

#### Timepoint

Before the start of the operation, 5 minutes after the start of the operation, every 15 minutes until the end of the operation

#### Method of measurement

Pulse oximeter

## Secondary outcomes

### 1

#### Description

Hypertension

#### Timepoint

Before the start of the operation, 5 minutes after the start of the operation, every 15 minutes until the end of the operation

#### Method of measurement

In millimeters of mercury using a Calibrated Barometer

### 2

#### Description

Hypotension

### Timepoint

Before the start of the operation, 5 minutes after the start of the operation, every 15 minutes until the end of the operation

### Method of measurement

In millimeters of mercury using a Calibrated Barometer

### 3

#### Description

Tachycardia

#### Timepoint

Before the start of the operation, 5 minutes after the start of the operation, every 15 minutes until the end of the operation

#### Method of measurement

Cardiac Monitor device

### 4

#### Description

Bradycardia

#### Timepoint

Before the start of the operation, 5 minutes after the start of the operation, every 15 minutes until the end of the operation

#### Method of measurement

Cardiac Monitor device

## Intervention groups

### 1

#### Description

Intervention group: 0.5 mg/kg of intravenous osmolol, whose volume will be increased to 20 cc by sterile normal saline, 5 minutes before the injection of sedative and sedative drugs and will be intravenously infused within two minutes.

#### Category

Prevention

### 2

#### Description

Intervention group: 0.2 mg/kg body weight of intravenous labetalol, whose volume will be increased to 20 cc by sterile normal saline, will be intravenously infused within two minutes 5 minutes before the injection of sedative and sedative drugs.

#### Category

Prevention

## Recruitment centers

### 1

#### Recruitment center

##### Name of recruitment center

Feiz hospital

##### Full name of responsible person

Darioush Moradi Farsani

**Street address**

Ayatollah Motahari Street , Qods Sq

**City**

Esfahan

**Province**

Isfahan

**Postal code**

8149644874

**Phone**

+98 31 3445 2034

**Email**

E-mail.feiz@mui.ac.ir

**Sponsors / Funding sources****1****Sponsor****Name of organization / entity**

Esfahan University of Medical Sciences

**Full name of responsible person**

Darioush Moradi Farsani

**Street address**

Hezarjerib St ,Azadi Sq

**City**

Esfahan

**Province**

Isfahan

**Postal code**

8164945811

**Phone**

+98 31 3662 4796

**Email**

Dmoradi@med.mui.ac.ir

**Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Esfahan University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

*empty*

**Country of origin****Type of organization providing the funding**

Academic

**Person responsible for general inquiries****Contact****Name of organization / entity**

Esfahan University of Medical Sciences

**Full name of responsible person**

Darioush Moradi Farsani

**Position**

Assistant Professor

**Latest degree**

Subspecialist

**Other areas of specialty/work**

Anesthesiology

**Street address**

Block 8 , Kouye Bahar , Hezarjerib St

**City**

Esfahan

**Province**

Isfahan

**Postal code**

8169615738

**Phone**

+98 31 4754 7767

**Email**

Dmoradi@med.mui.ac.ir

**Person responsible for scientific inquiries****Contact****Name of organization / entity**

Esfahan University of Medical Sciences

**Full name of responsible person**

Darioush Moradi Farsani

**Position**

Assistant Professor

**Latest degree**

Subspecialist

**Other areas of specialty/work**

Anesthesiology

**Street address**

Block 8 , Kouye bahar , Hezarjerib St

**City**

Esfahan

**Province**

Isfahan

**Postal code**

8169615738

**Phone**

+98 31 4754 7767

**Email**

Dmoradi@med.mui.ac.ir

**Person responsible for updating data****Contact****Name of organization / entity**

Esfahan University of Medical Sciences

**Full name of responsible person**

Amirreza Abbasi

**Position**

Medical intern

**Latest degree**

Medical doctor

**Other areas of specialty/work**

Anesthesiology

**Street address**

Hezarjerib Street

**City**

Esfahan

**Province**

Isfahan

**Postal code**

8169615738

**Phone**

+98 31 3262 0262

**Email**

Amirrezaabbasi00@gmail.com

## Sharing plan

**Deidentified Individual Participant Data Set (IPD)**

Yes - There is a plan to make this available

**Study Protocol**

Undecided - It is not yet known if there will be a plan to make this available

**Statistical Analysis Plan**

Undecided - It is not yet known if there will be a plan to make this available

**Informed Consent Form**

Undecided - It is not yet known if there will be a plan to make this available

**Clinical Study Report**

Undecided - It is not yet known if there will be a plan to make this available

**Analytic Code**

Undecided - It is not yet known if there will be a plan to make this available

**Data Dictionary**

Undecided - It is not yet known if there will be a plan to make this available

**Title and more details about the data/document**

Information related to the effectiveness of esmolol and labtalol in reducing cardiovascular complications in cataract surgery candidates with chronic hypertension.

**When the data will become available and for how long**

Start the access period up to one year after the results are published

**To whom data/document is available**

Researchers

**Under which criteria data/document could be used**

Can be used for secondary studies

**From where data/document is obtainable**

Correspond with dmoradi@med.mui.ac.ir

**What processes are involved for a request to access data/document**

Will be sent after receiving the email

**Comments**